219results about "Polypeptide with enzyme fusion" patented technology

The invention discloses a recombinant fusion protein of a human lambda light-chain single-chain antibody, a DNA (deoxyribonucleic acid) molecule, a library building method and application, and the recombinant fusion protein of the human lambda light-chain single-chain antibody is the recombinant fusion protein formed by connecting the human lambda light-chain single-chain antibody, phage Piii protein and luciferase, the amino acid sequence of the recombinant fusion protein of the human lambda light-chain single-chain antibody is shown as SEQ ID NO: 5, the recombinant fusion protein library of the human lambda light-chain single-chain antibody has large capacity, the established single-chain antibody TG1 library is more than 1 * 10 < 9 > cfu / mL, positive clones capable of being combined with ligands can be screened and enriched for multiple rounds, and the recombinant fusion protein library has the characteristics of high sensitivity, high signal-to-noise ratio and the like.

The invention discloses a cell and a method for detecting the activity of a GLP-1R / GIPR double-target agonist drug. The invention relates to a cell for co-expressing GLP-1R, GIPR and CRE-miniP-luciferase reporter genes, and provides a method for detecting the biological activity of a GLP-1R / GIPR double-target agonist drug based on the cell, and the method is simple to operate, short in test period, sensitive in reaction, small in variability, strong in specificity and high in accuracy, can be used for release inspection of products, and can be used for detecting the biological activity of the GLP-1R / GIPR double-target agonist drug. The method has important significance on quality control and clinical application of GLP-1R / GIPR double-target agonist drugs.

Provided herein are co-assembling peptides which may form granules under stimulating conditions. Also provided herein are protein carrying granules. Further provided herein, are methods of making each of the co-assembling peptides and granules.

Provided herein are compositions comprising a double-stranded RNA (dsRNA) binding domains linked to components of a complementation system. Upon binding of a pair of dsRNA binding domains to a dsRNA, a detectable complex of the complementation components is formed, and the dsRNA can be detected / quantified.

The invention relates to antibody conjugates (e.g., a bispecific antibody), drug and nanoparticle compositions and methods and compositions for generating them. This invention further relates to methods of using these compositions for imaging, diagnosing or treating a disease.

To provide a medical drug for treating Tie2 pathway-mediated disorder which includes a conjugate that binds to Tie2.SOLUTION: A medical drug in which a conjugate includes 2, 3, 4, 5, 6, 7 or 8 antibodies linked to a multimerization domain or an antigen-binding fragment thereof, and each of the antibodies or an antigen-binding fragment thereof binds to Tie2, and includes: a heavy chain variable domain (VH) including (a) CDR-H1 including amino acid sequence NTDIS (sequence number 3), (b) CDR-H2 including amino acid sequence RISPSDGNTYYADSVKG (sequence number 4) and (c) CDR-H3 (VH) including amino acid sequence RTRWASWAFDY (sequence number 7); and a light chain variable domain (VL) including (d) CDR-L1 including amino acid sequence RASQDVSTAVA (sequence number 8), (e) CDR-L2 including amino acid sequence SASFLYS (sequence number 9) and (f) CDR-L3 including amino acid sequence QQSYTTPPT (sequence number 10).SELECTED DRAWING: None

To provide a Tie-2 antibody and a fragment and a conjugate thereof, and a method for using them.SOLUTION: Provided is an isolated antibody that specifically binds to Tie2, or an antigen-binding fragment thereof, which includes: a heavy chain variable domain (VH) which includes CDR-H1 including an amino acid sequence NTDIS, CDR-H2 including an amino acid sequence RISPSDGNTYYADSVKG, and CDR-H3 including an amino acid sequence RTRWASX1AX2DY, where X1 denotes M, L, K, F, Y, R, N, Q, H or W, and / or X2 denotes F, Y, L, Q, I, K or H; and a light chain variable domain (VL) which includes (d) CDR-L1 including an amino acid sequence RASQDVSTAVA, (e) CDR-L2 including amino acid sequence SASFLYS, and (f) CDR-L3 including an amino acid sequence QQSYTTPPT.SELECTED DRAWING: None

The invention relates to the technical field of biology, in particular to a method for stably improving the titer of horse radish peroxidase labeled streptavidin. According to the method provided by the invention, streptavidin with different histidine label lengths is designed, and then the streptavidin is coupled with horse radish peroxidase oxidized by sodium periodate, so that high-titer horse radish peroxidase labeled streptavidin can be obtained. The invention also discloses application of the enzyme-labeled conjugate in a magnetic particle platform streptavidin-biotin system, and experimental results prove that the method provided by the invention can be used for stably preparing the enzyme conjugate with high titer and low background, and is widely applied in the streptavidin-biotin system.

The present invention provides compounds and methods of use thereof for assessing target engagement for DNA polymerase theta. In particular, provided herein are tracer compounds comprising a small molecule that binds DNA polymerase theta tethered to a fluorophore, and methods of use thereof in target engagement assays.

Provided herein is a system for delivering genetical material, preferably subcutaneously, and its various elements. Also provided are related compositions and methods.

The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

The invention provides a single-chain and double-protein-expressed circular RNA construct and a preparation method and application thereof, and the single-chain and double-protein-expressed circular RNA construct comprises 5'and 3 'introns used for realizing RNA self-splicing and cyclization as a first kind of introns; the 5'and 3 'homologous arms are used as pairing sites in RNA molecules; the exon 1 and the exon 2, which are connected after being spliced, can be spliced and connected together under the action of the first type of introns to form a complete and continuous open reading frame; an interval sequence for providing spatial and adjustment sequence structures; the IRES is used for starting translation; a glycine-serine linker as a flexible linker; a green fluorescent protein for gene expression monitoring; a luciferase for producing light by a catalytic chemical reaction. All the advantages of the double-IRES system for generating natural complete protein are reserved, and the core defect of low efficiency can be thoroughly overcome.

Provided are a conjugate comprising an IgA protease or variants thereof, and a polyethylene glycol (PEG) moiety, as well as uses thereof in treating diseases associated with IgA deposition (e.g., IgA nephropathy).

Provided herein are compositions comprising a particle comprising a library encoded bead (e.g., DEL bead) coated in a polymeric matrix forming a core-shell particle, wherein the core-shell particle is further inside a 3D tissue culture. Also provided herein are methods of making such particles, and methods of using such particles for drug discovery such as identification of bioactive compounds via high-throughput cellular activity-based phenotypic screens of DNA-encoded chemical library beads.

Systems and techniques are provided for making genetically engineered ion channels (ICs) with bioluminescent resonance energy transfer (BRET) complexes and using such ICs for efficient readout of neural activity and output of biological neuronal networks.SOLUTION: In one implementation, the disclosed technology includes identifying a target location in the IC for expression of a target protein including a donor tag protein and an acceptor tag protein, and modifying the genome of the neuronal cell at a portion associated with the target location in the IC. The technique further includes causing the neuronal cell to express the target protein in the IC according to the modified genome. In the first (second) state of the IC, the donor tag protein is at a first (second) distance from the acceptor tag protein that is related to the absence (presence) of energy transfer between the donor tag protein and the acceptor tag protein.SELECTED DRAWING: Figure 3A-3C

The present disclosure provides polypeptides that can be used in a complementation assay as a biosensor. In certain aspects, the polypeptide is a larger component of a split luciferase, wherein the luciferase is derived from LuxSit. The polypeptide may comprise an amino acid sequence having at least 85% identity to the amino acid sequence: of SEQ ID NO:1 and comprises D at position 30, N at position 46, R at position 58, R at position 61, F at position 64, T at position 68, E at position 101, and A at position 103; G at position 9, D at position 30, D at position 54, F at position 64, K at position 68, and E at position 101; D at position 30, D at position 46, K at position 68, and E at position 101; S at position 9, D at position 30, L at position 43, D at position 46, G at position 54, F at position 64, K at position 68, E at position 101, and T at position 103; D at position 30, D at position 46, F at position 64, K at position 68, E at position 101, and T at position 103; N at position 30, D at position 46, E at position 101, and A at position 103; or D at position 30, N at position 46, F at position 64, T at position 68, E at position 101, and A at position 103, wherein the numbering of the amino acid positions is based on the numbering of the amino acids in SEQ ID NO:1.

Provided herein is a vaccine against RSV. The vaccine comprises an mRNA encoding a stabilised prefusion RSV F protein immunogen linked to a scaffold based on lumazine synthase.

Disclosed are methods of RNA-triggered protein cleavage by the CRISPR Cas7-11-Csx29 complex. A guide RNA specifically hybridizes to a RNA target, and Csx29 cleaves Csx30 when Cas7-11 :Csx29 complex binds to the target RNA.

The invention relates to a chimeric antigen-receptor polypeptide heterodimer comprising two polypeptides, wherein the first contains an extracellular part of the major histocompatibility complex I alpha chain and the second contains a β2-microglobulin domain, or the first contains an extracellular part of the major histocompatibility complex Il alpha chain and the second contains a major histocompatibility complex Il beta chain. One of the polypeptides further contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor alpha chain and the other one contains a transmembrane domain, a hinge region and an intracellular domain of the T cell receptor beta chain, and additionally an antigen-peptide covalently linked to said extracellular MHC domain. The invention further relates to a method for the identification of a TCR recognizable peptide sequence making use of the heterodimer of the invention.

Trypsin / trypsin-like proteases have been reported to be facilitating SARS-CoV-2 entry into host cells. Spike has protease cleavage sites between the S1 and S2 domains. Cleavage property of proteases can be used to design drug screening assays meant for screening antiviral candidates against spike cleavage. In the claimed invention we have developed a proof-of-concept assay system for screening drugs against proteases which cleave spike between S1 and S2. We designed a fusion substrate protein containing a reporter protein, the protease cleavage site between S1 and S2 and a cellulose binding domain. The substrate protein can be immobilized on cellulose due to the presence of cellulose binding domain (CBD). When proteases cleave the substrate, CBD remains bound to cellulose and the reporter protein is dislodged. The released reporter can be used as read out of protease activity.

Provided herein are vaccines against RSV. In some embodiments, the vaccine comprises an mRNA encoding a stabilized pre-fusion RSV F protein immunogen linked to a dioxotetrahydropteridine synthase based scaffold.

This specification provides compositions and systems comprising complementary tags and reporters for labeling and detecting targets by luminescence and a second mode (e.g., fluorescence), as well as methods for using them. In particular, a tag comprising a fusion of a first component of a bioluminescent complex and a first component of a modified dehalogenase complex is provided; a reporter comprising a second component of a bioluminescent complex and a second component of a modified dehalogenase complex is provided; and systems and methods comprising the tags and reporters described herein for dual-mode labeling and target detection are provided.

The present invention relates to in vitro methods of (a) determining whether a compound induces proximity between (i) a target protein and (ii) a Cullin-RING E3 ubiquitin ligase complex; (b) of screening a plurality of different compounds for the ability of a compound of said plurality of different compounds to induce proximity between (i) and (ii); (c) confirming that a compound induces proximity between (i) and (ii); and (d) of improving the ability of a compound to induce proximity between (i) and (ii) to arrive at an improved compound.

Antigen-binding proteins, nucleic acid constructs encoding antigen-binding proteins, vectors containing nucleic acid constructs, and host cells containing the vectors and nucleic acid constructs, as well as kits for producing antigen-binding proteins, are provided.

The invention belongs to the technical field of biology, and particularly relates to a bovine viral diarrhea virus NS2 truncated protein and application thereof in BVDV antibody detection. The invention firstly provides a truncated protein of a BVDV NS2 protein, the truncated protein is subjected to soluble expression after being fused with glutathione S transferase (GST) and horse radish peroxidase (HRP) respectively, has better reactogenicity with positive serum of a BVDV antibody, does not react with negative serum of the BVDV antibody, and can be used for detecting the BVDV antibody; secondly, a fusion protein of GST and the truncated protein is taken as a coating antigen, a fusion protein of HRP and the truncated protein is taken as a detection antigen, a double-antigen sandwich ELISA method for BVDV antibody detection is constructed, and the method has the technical advantages of high sensitivity, good specificity, simplicity and convenience in operation, easiness in popularization, low cost and the like, and can be applied to screening of BVDV antibodies in cattle.

The purpose of the present invention is to provide an evaluation system that enables less invasive, over-time and systemic detection of an extracellular purinergic receptor ligand. Provided is a transgenic nonhuman animal that expresses a first fused protein and a second fused protein for detecting a purinergic receptor ligand present outside cells, wherein the first fused protein contains a membrane protein capable of binding to the purinergic receptor ligand and a first reporter protein and the second fused protein contains a protein capable of binding to the membrane protein to which the ligand is bound and a second reporter protein. Also provided is a cell of the transgenic nonhuman animal.

The present invention relates to the field of biotechnology, and in particular to the preparation and application of a CD56 protein-specific nanoantibody-HRP fusion protein. The present application discloses a CD56 protein-specific nanoantibody-HRP fusion protein and a preparation method thereof, as well as the application of the fusion protein in preparing a product for detecting CD56 protein-specific antibodies in serum. The HRP-fused nanoantibody prepared in the present application constructs a fusion protein of a primary antibody and a labeled HRP through genetic engineering, converting two molecular hybridizations into one molecular hybridization, which can greatly shorten the duration of enzyme-linked immunosorbent assay and improve the accuracy. Compared with traditional antibodies, nanoantibodies are easier to genetically manipulate and can be coupled with a variety of labeled enzymes.

Compositions for detecting agents causing lymphatic filariasis, including Wuchereria bancrofti, are provided, including the antigen Wb5 or fusion proteins including Wb5 linked to a reporter protein or tag. Nucleic acids encoding the Wb5 protein or the fusion proteins, vectors including the nucleic acids, and host cells including the nucleic acids or vectors are also provided. Methods of detection of antibodies to Wb5 in a sample from a subject, including immunoassay methods are also provided.